Yucel Arman1, Adem Atici2, Ozgur Altun1, Remzi Sarikaya3, Sengül Aydin Yoldemir4, Murat Akarsu5, Orkide Kutlu1, Guzin Zeren Ozturk6, Pinar Demir1, Mustafa Ozcan1, Recep Yilmaz Bayraktarli7, Tufan Tukek8. 1. University of Health Sciences, Prof Dr Cemil Tascioglu City Hospital, Department of Internal Medicine, Istanbul - Turquia. 2. Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Department of Cardiology, Istanbul - Turquia. 3. University of Health Sciences, Van Education and Research Hospital, Department of Cardiology, Van - Turquia. 4. University of Health Sciences, Istanbul Bakirkoy Dr Sadi Konuk Training and Research Hospital, Department of İnternal Medicine, Istanbul - Turquia. 5. University of Health Sciences, Kanunİ Sultan Suleiman Traİnİng and Research Hospİtal, Department of İnternal Medicine, Istanbul - Turquia. 6. University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Family Medicine, Istanbul - Turquia. 7. University of Health Sciences, Prof Dr Cemil Tascioglu City Hospital, Department of Radiology, Istanbul - Turquia. 8. Istanbul University, Istanbul Faculty of Medicine, Department of İnternal Medicine, Istanbul - Turquia.
Abstract
BACKGROUND: Patients with prediabetes have an increased risk of atherosclerotic cardiovascular disease; therefore, early detection is important. OBJECTIVE: The present study aimed to reveal the usability of serum endocan levels as a biomarker in the diagnosis of subclinical atherosclerosis in patients with prediabetes, based on CIMT measurements. METHODS: Participants were classified according to the presence (n=42) or absence (n=42) of prediabetes. Serum endocan, fasting blood sugar, fasting insulin, and glycated hemoglobin (HbA1c) values of patients were examined, and CIMT was measured. The level of significance for statistical analysis was 0.05. RESULTS: While serum endocan levels were found to be lower in patients with prediabetes, when compared to the control group (p=0.042), CIMT values were found to be higher (p=0.046). When evaluated by multivariate regression analysis, the serum endocan level was found to be associated with CIMT, regardless of other parameters (p=0.007). A negative correlation was found between plasma fasting insulin and endocan levels (r=-0.320, p=0.001). CONCLUSIONS: Carotid intima media thickness was found to be high and the serum endocan level was low in patients with prediabetes. Decreased serum endocan levels in patients with prediabetes may be a contributing factor to atherosclerosis formation mechanisms.
BACKGROUND: Patients with prediabetes have an increased risk of atherosclerotic cardiovascular disease; therefore, early detection is important. OBJECTIVE: The present study aimed to reveal the usability of serum endocan levels as a biomarker in the diagnosis of subclinical atherosclerosis in patients with prediabetes, based on CIMT measurements. METHODS: Participants were classified according to the presence (n=42) or absence (n=42) of prediabetes. Serum endocan, fasting blood sugar, fasting insulin, and glycated hemoglobin (HbA1c) values of patients were examined, and CIMT was measured. The level of significance for statistical analysis was 0.05. RESULTS: While serum endocan levels were found to be lower in patients with prediabetes, when compared to the control group (p=0.042), CIMT values were found to be higher (p=0.046). When evaluated by multivariate regression analysis, the serum endocan level was found to be associated with CIMT, regardless of other parameters (p=0.007). A negative correlation was found between plasma fasting insulin and endocan levels (r=-0.320, p=0.001). CONCLUSIONS: Carotid intima media thickness was found to be high and the serum endocan level was low in patients with prediabetes. Decreased serum endocan levels in patients with prediabetes may be a contributing factor to atherosclerosis formation mechanisms.
Authors: Matthias W Lorenz; Joseph F Polak; Maryam Kavousi; Ellisiv B Mathiesen; Henry Völzke; Tomi-Pekka Tuomainen; Dirk Sander; Matthieu Plichart; Alberico L Catapano; Christine M Robertson; Stefan Kiechl; Tatjana Rundek; Moïse Desvarieux; Lars Lind; Caroline Schmid; Pronabesh DasMahapatra; Lu Gao; Kathrin Ziegelbauer; Michiel L Bots; Simon G Thompson Journal: Lancet Date: 2012-04-27 Impact factor: 79.321
Authors: James H Stein; Claudia E Korcarz; R Todd Hurst; Eva Lonn; Christopher B Kendall; Emile R Mohler; Samer S Najjar; Christopher M Rembold; Wendy S Post Journal: J Am Soc Echocardiogr Date: 2008-02 Impact factor: 5.251
Authors: I Balta; S Balta; S Demirkol; D P Mikhailidis; T Celik; M Akhan; O Kurt; Y G Kurt; I Aydin; S Kilic Journal: Br J Dermatol Date: 2013-11 Impact factor: 9.302
Authors: A Klisic; N Kavaric; S Vujcic; M Mihajlovic; A Zeljkovic; J Ivanisevic; V Spasojevic-Kalimanovska; A Ninic; J Kotur-Stevuljevic; J Vekic Journal: Eur Rev Med Pharmacol Sci Date: 2020-08 Impact factor: 3.507